Sugi Predict

Sugi Predict / Compounds / SCHEMBL850882

SCHEMBL850882

SCHEMBL850882

CC(C)OC(=O)[C@H](C)NP(=O)(Oc1ccccc1)Oc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTN3A1 O00481 3/20 0.48
▸ ALDH1A1 P00352 2/20 0.46
▸ CA1 P00915 1/20 0.46
▸ CA2 P00918 1/20 0.46
▸ CES2 O00748 1/20 0.46
▸ CES1 P23141 1/20 0.46
▸ MEN1 O00255 4/20 0.45
▸ KMT2A Q03164 4/20 0.45
▸ NPC1 O15118 2/20 0.44
▸ RAB9A P51151 2/20 0.44
▸ MAPT P10636 2/20 0.44
▸ HTT P42858 1/20 0.44
▸ FFAR1 O14842 1/20 0.44
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ LMNA P02545 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ MITF O75030 1/20 0.42
▸ POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15588696 1.00 BTN3A1 (0.48) BTN3A1ALDH1A1CA1CA2CES2
SCHEMBL20059213 1.00 BTN3A1 (0.48) BTN3A1ALDH1A1CA1CA2CES2
SCHEMBL851467 1.00 BTN3A1 (0.48) BTN3A1ALDH1A1CA1CA2CES2
SCHEMBL13051654 1.00 BTN3A1 (0.48) BTN3A1ALDH1A1CA1CA2CES2
SCHEMBL851091 1.00 BTN3A1 (0.48) BTN3A1ALDH1A1CA1CA2CES2
SCHEMBL15457700 1.00 BTN3A1 (0.48) BTN3A1ALDH1A1CA1CA2CES2
SCHEMBL28842286 1.00 BTN3A1 (0.48) BTN3A1ALDH1A1CA1CA2CES2
SCHEMBL17601834 0.96 CA1 (0.49) BTN3A1ALDH1A1CA1CA2CES2
SCHEMBL16892447 0.93 BTN3A1 (0.44) BTN3A1ALDH1A1CA1CA2CES2
SCHEMBL30770430 0.92 KMT2A (0.47) ALDH1A1CA1CA2CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106565805-B Preparation method of sofosbuvir 常州市勇毅生物药业有限公司 2020-04-14 — — CN claimed
US-20100298257-A1 NUCLEOSIDE PHOSPHORAMIDATES PHARMASSET, INC. (US) 2010-11-25 — — US claimed
US-20260109724-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES INC (US) 2026-04-23 — — US disclosed
CN-115175735-B Antiviral compounds 吉利德科学公司 2025-03-04 — — CN disclosed
US-20250057867-A1 NUCLEOSIDE PHOSPHORAMIDATES GILEAD SCIENCES INC (US) 2025-02-20 — — US disclosed
US-20250034186-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2025-01-30 — — US disclosed
CN-118852172-A 5- (4-Aminopyrrolo [2,1-f ] [1,2,4] triazin-7-yl) -2-cyano-3, 4-dihydroxytetrahydrofuran derivatives as antiviral agents 吉利德科学公司 2024-10-29 — — CN disclosed
CN-118459515-A Preparation method of 2 '-azidoamide-6' -mannoside-phosphate compound 杭州瑞奥生物医药有限公司 2024-08-09 — — CN disclosed
US-12054507-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2024-08-06 — — US disclosed
CN-115103680-B 5- (4-Aminopyrrolo [2,1-f ] [1,2,4] triazin-7-yl) -2-cyano-3, 4-dihydroxytetrahydrofuran derivatives as antiviral agents 吉利德科学公司 2024-07-23 — — CN disclosed
US-20230382931-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER MEDIVIR AB (SE) 2023-11-30 — — US disclosed
WO-2011123672-A1 PURINE NUCLEOSIDE PHOSPHORAMIDATE PHARMASSET, INC. (US) 2011-10-06 — — WO disclosed
WO-2011123668-A2 STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES PHARMASSET, INC. (US) 2011-10-06 — — WO disclosed
WO-2011123645-A2 NUCLEOSIDE PHOSPHORAMIDATES PHARMASSET, INC. (US) 2011-10-06 — — WO disclosed
WO-2011123645-A2 NUCLEOSIDE PHOSPHORAMIDATES PHARMASSET, INC. (US) 2011-10-06 — — WO disclosed
WO-2010135569-A1 N- [ (2 ' R) -2 ' -DEOXY-2 ' -FLUORO-2 ' -METHYL-P-PHENYL-5 ' -URIDYLYL] -L-ALANINE 1-METHYLETHYL ESTER AND PROCESS FOR ITS PRODUCTION PHARMASSET, INC. (US) 2010-11-25 — — WO disclosed
WO-2010135569-A1 N- [ (2 ' R) -2 ' -DEOXY-2 ' -FLUORO-2 ' -METHYL-P-PHENYL-5 ' -URIDYLYL] -L-ALANINE 1-METHYLETHYL ESTER AND PROCESS FOR ITS PRODUCTION PHARMASSET, INC. (US) 2010-11-25 — — WO disclosed
US-20100298257-A1 NUCLEOSIDE PHOSPHORAMIDATES PHARMASSET, INC. (US) 2010-11-25 — — US disclosed
US-20100298257-A1 NUCLEOSIDE PHOSPHORAMIDATES PHARMASSET, INC. (US) 2010-11-25 — — US disclosed
US-20100298257-A1 NUCLEOSIDE PHOSPHORAMIDATES PHARMASSET, INC. (US) 2010-11-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260109724-A1 ANTIVIRAL COMPOUNDS IRF3, IFNAR1, HAVCR2 BTN3A1 4156/4885ALDH1A1 744/4885CA1 4447/4885
US-20250057867-A1 NUCLEOSIDE PHOSPHORAMIDATES PNP, RNGTT, NSUN2 BTN3A1 3601/4885ALDH1A1 3204/4885CA1 4843/4885
US-20100298257-A1 NUCLEOSIDE PHOSPHORAMIDATES PNP, RNGTT, NSUN2 BTN3A1 3738/4885ALDH1A1 3043/4885CA1 4847/4885
US-12054507-B2 Antiviral compounds MAVS, HAVCR2, SNRPA BTN3A1 3868/4885ALDH1A1 756/4885CA1 4862/4885
US-20250034186-A1 ANTIVIRAL COMPOUNDS MAVS, HAVCR2, SNRPA BTN3A1 3780/4885ALDH1A1 861/4885CA1 4869/4885
US-20230382931-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER ADORA3, DUT, NTPCR BTN3A1 1653/4885ALDH1A1 382/4885CA1 4799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback